In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

SCYNEXIS, Inc.. Trade Record

NASDAQ:SCYX SCYNEXIS, Inc. stock gains 29.17% Exit Jun 4, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart SCYX May 11, 2018, priceSeries
About SCYNEXIS, Inc.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
87.27
Entry Date
May 11, 2018
Entry Price
1.27
Sell Date
Jun 4, 2018
Sell Price
1.64
Net Gain
29.17%
Hold Time
15 Trading Days